Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome

Metabolic Syndrome and Related Disorders

Volumn 4, Issue 2, 2006, Pages 122-128

  Tarkun, Ilhan ^a,b   Çetinarslan, Berrin ^a   Türemen, Erdem ^a   Cantürk, Zeynep ^a   Biyikli, Mithat ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; INTERLEUKIN 6; LIPID; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID ANALYSIS; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATIENT PARTICIPATION; PELVIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; WAIST CIRCUMFERENCE;

EID: 33746422560     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.4.122     Document Type: Article

References (38)

1. Dunaif A. Insulin resistance and polcystic ovary syndrome: mechanism and implications for pathogenesis. Endocrinol Rev 1997;18:345-349.
2. Nestler JE. Insulin resistance and plycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 2000;78:345-349.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
4. Moghetti P. Insulin resistance: what is its role in the polycystic ovary syndrome? Curr Opin Endocrinol Diabetes 2000;9:444-450.
5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
6. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF-α by human muscle. Relationship to insulin resistance. J Clin Invest 1996;97: 1111-1116.
7. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996;271:665-668.
8. Fernandez-Real JM, Vayreda R, Richart J, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin-6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-1159.
9. Vazarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RA. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414-417.
10. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human adiposity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.
11. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-3342.
12. Southern C, Schulster D, Gren JC. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. Biochem J 1990;272:243-245.
13. Sandler S, Bendtzen K, Eizirik D, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990;126:1288-1294.
14. Akira T, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81: 19-24.
16. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1962;21:1440-1447.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trecher DF, Turner DC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
18. Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
19. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
20. Dunaif A. Insulin resistance in polycystic ovarian syndrome. Ann NY Acad Sci 1993;683:60-64.
21. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004;60:1-17.
22. Tarkun I, Çetinarslan B, Cantürk Z, Türemen E, Şahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89:5592-5596.
23. Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L. İnsulin sensitivity and beta cell function in women with polycysfic ovary syndrome. Diabetes Care 2002;25:1217-1222.
24. Hotamisligil GS. The role of TNFα and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.
25. Jasper M, Norman RJ. Immunoreactive interleukin-1 beta and tumor necrosis factor-α in thecal, stromal and granulasa cell cultures from normal and polycystic ovaries. Hum Reprod 1995;10:1352-1354.
26. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6 and vascular endothelial growth factor. Fertil Steril 1999; 71:482-489.
27. Escobar-Morreale HF, Calvo RM, Sancho J, San Millan JL. TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab 2001;86:3761-3767.
28. Gonzalez E, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor-α an normal-weight women with polycystic ovary syndrome. Metabolism 1999;48: 437-441.
29. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, Bellastella A, Carella C, Izzo A. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Am Coll Obstet Gynecol 2003;101:1177-1181.
30. Hotamisligil GS, Arner PR, Atkinson RL, Spiegelmen BM. Differential regulation of the p80 TNF receptor in human obesity and insulin resistance. Diabetes 1997;46:451-455.
31. Kern PA, Soghizadech M, Ong JM, Bosch RJ, Peem R, Simsolo EB. The expression of TNF in human adipose tissue. Regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest 1995;5:211-219.
32. Gasteyger C, Tremblay A. Metabolic impact of body fat distribution. J Endocrinol Invest 2002;25:876-883.
33. Garaluet M, Perex-Llamas F, Fuente T, Zamara S, Tebart FJ. Anthropemetric, computed tomography and fat cell data in obese population: relationship with insulin, leptin, tumor necrosis factor-α, sex hormone binding globulin and sex hormones. Eur J Endocrinol 2000;143:657-666.
34. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
35. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40: 1286-1292.
36. Pickup JC, Crook MA. Is type 2 diabetes a disease of innate immune system? Diabetologia 1998;41:1 241-1248.
37. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997;82:4167-4170.
38. Hanson K, Pratley R. Interleukin-6 is associated with insulin resistance independently of obesity. Diabetes 2000;49:A297.